{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T16:44:28Z","timestamp":1770569068060,"version":"3.49.0"},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T00:00:00Z","timestamp":1712188800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["MOH-CIRG21jun-0005"],"award-info":[{"award-number":["MOH-CIRG21jun-0005"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["MOH-CSAINV22jul-0005"],"award-info":[{"award-number":["MOH-CSAINV22jul-0005"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Peritoneal sarcomatosis (PS) is a difficult entity to treat with limited options and guarded prognosis. We aimed to determine if the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) could offer superior local recurrence-free survival in patients with retroperitoneal sarcoma at high risk of developing PS as opposed to extended resection alone.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>This is a single arm, phase II intervention study where all patients with recurrent localized retroperitoneal sarcoma considered at high risk of developing PS were considered for enrolment (ClinicalTrials.gov identifier: NCT03792867). Upon enrolment, patients underwent vigorous preoperative testing to ensure fitness for the procedure. During surgery, patients underwent extended resection and HIPEC with doxorubicin. Patients were followed-up every 2 weeks (\u00b1 10 days) for the first month and subsequently every three months (\u00b1 1 month) up to a year post-surgery, and were assessed for potential chemotherapy toxicity and post-treatment complications. After a year from resection and HIPEC, patients were followed-up either during routine clinic review or contacted via telephone every year (\u00b1 1 month) for 3 years.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Six patients were recruited but one patient dropped out due to adverse and unexpected intraoperative events. The remaining patients completed the procedure uneventfully. Post-HIPEC, all patients recurred with a disease-free interval ranging from six to 24 months. Three patients died due to complications from recurrent disease whereas the remaining three patients are alive as of their last visit. The overall survival at time at reporting ranged between 22 to 56 months.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>The procedure is feasible with no major morbidity to patients. However, we are unable to recommend for it to be implemented as a routine procedure at this current stage due to lack of improved survival outcomes. Further multi-institutional studies may be conducted to yield better results.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0300594","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T17:49:48Z","timestamp":1712252988000},"page":"e0300594","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Radical resection and hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of high risk recurrent retroperitoneal sarcoma\u2014A pilot study in a tertiary Asian centre"],"prefix":"10.1371","volume":"19","author":[{"given":"Chin Jin","family":"Seo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6620-6085","authenticated-orcid":true,"given":"Joey Wee-Shan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamad","family":"Farid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jolene Si Min","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khee Chee","family":"Soo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claramae Shulyn","family":"Chia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4573-7738","authenticated-orcid":true,"given":"Chin-Ann Johnny","family":"Ong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2024,4,4]]},"reference":[{"key":"pone.0300594.ref001","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/SLA.0000000000001149","article-title":"Histology-based Classification Predicts Pattern of Recurrence and Improves Risk Stratification in Primary Retroperitoneal Sarcoma","volume":"263","author":"MCB Tan","year":"2016","journal-title":"Ann Surg"},{"key":"pone.0300594.ref002","volume-title":"WHO classification of tumours of soft tissue and bone","author":"CDM Fletcher","year":"2013","edition":"4"},{"issue":"3","key":"pone.0300594.ref003","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/01.sla.0000086542.11899.38","article-title":"Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma","volume":"238","author":"S Singer","year":"2003","journal-title":"Ann Surg"},{"issue":"12","key":"pone.0300594.ref004","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1002\/cncr.21933","article-title":"Retroperitoneal liposarcomas: follow-up analysis of dedifferentiation after clinicopathologic reexamination of 86 liposarcomas and malignant fibrous histiocytomas","volume":"106","author":"E Fabre-Guillevin","year":"2006","journal-title":"Cancer"},{"key":"pone.0300594.ref005","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1245\/s10434-014-3965-2","article-title":"Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: A Consensus Approach From the Trans-Atlantic RPS Working Group.","volume":"22","author":"Trans-Atlantic RPS Working Group.","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"pone.0300594.ref006","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1245\/s10434-010-1229-3","article-title":"Systematic review on the efficacy of multimodal treatment of sarcomatosis with cytoreduction and intraperitoneal chemotherapy","volume":"18","author":"G Munene","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"pone.0300594.ref007","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/jso.21031","article-title":"The role of surgical margin status in retroperitoneal sarcoma","volume":"98","author":"DA Anaya","year":"2008","journal-title":"Journal of Surgical Oncology"},{"key":"pone.0300594.ref008","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ijscr.2019.09.009","article-title":"Long-term survival is possible using cytoreductive surgery plus HIPEC for sarcomatosis-Case report of 2 patients.","volume":"64","author":"PH Sugarbaker","year":"2019","journal-title":"Int J Surg Case Rep."},{"key":"pone.0300594.ref009","first-page":"3","volume-title":"Evolving Role of CRS and HIPEC: Current Indications.","author":"F Rajan","year":"2018"},{"key":"pone.0300594.ref010","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/FPC.0b013e32833ffb56","article-title":"Doxorubicin pathways: pharmacodynamics and adverse effects","volume":"21","author":"CF Thorn","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"pone.0300594.ref011","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","article-title":"Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a andomized controlled phase 3 trial.","volume":"15","author":"I Judson","year":"2014","journal-title":"Lancet Oncol"},{"key":"pone.0300594.ref012","first-page":"45","article-title":"Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy.","volume":"7","author":"MD Goodman","year":"2016","journal-title":"J Gastrointest Oncol"},{"key":"pone.0300594.ref013","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1634\/theoncologist.10-2-112","article-title":"Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy.","volume":"10","author":"PH Sugarbaker","year":"2005","journal-title":"Oncologist"},{"key":"pone.0300594.ref014","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","article-title":"Cancer statistics, 2012.","volume":"62","author":"R Siegel","year":"2012","journal-title":"CA Cancer J Clin."},{"key":"pone.0300594.ref015","first-page":"1533","volume-title":"Soft tissue sarcoma.","author":"S. Singer","year":"2011"},{"issue":"3","key":"pone.0300594.ref016","doi-asserted-by":"crossref","first-page":"271e81","DOI":"10.1097\/00000478-199703000-00002","article-title":"Dedifferentiated liposarcoma: a clinicopathological analysis of 155 cases with a proposal for an expanded definition of dedifferentiation.","volume":"21","author":"WH Henricks","year":"1997","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"pone.0300594.ref017","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/00000658-200203000-00015","article-title":"Analysis of the prognostic significance of microscopic margins in 2,084 localized primary adult soft tissue sarcomas","volume":"235","author":"A Stojadinovic","year":"2002","journal-title":"Ann Surg"},{"issue":"2","key":"pone.0300594.ref018","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1053\/ejso.2001.1242","article-title":"Prognostic factors in soft tissue sarcomas: a study of 395 patients.","volume":"28","author":"PD Stefanovski","year":"2002","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"pone.0300594.ref019","doi-asserted-by":"crossref","first-page":"244e50","DOI":"10.1097\/01.sla.0000108670.31446.54","article-title":"Operative management of primary retroperitoneal sarcomas: a reappraisal of an institutional experience","volume":"239","author":"I Hassan","year":"2004","journal-title":"Ann Surg"},{"issue":"6","key":"pone.0300594.ref020","first-page":"1130e7","article-title":"Efficacy of hyperthermic intraperitoneal chemotherapy and cytoreductive surgery in the treatment of recurrent uterine sarcoma","volume":"28","author":"TP Diaz-Montes","year":"2018","journal-title":"Int J Gynecol Cancer"},{"issue":"6","key":"pone.0300594.ref021","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1177\/000313481307900624","article-title":"Votanopoulos KI; Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in peritoneal sarcomatosis","volume":"79","author":"RW Randle","year":"2013","journal-title":"Am Surg"},{"issue":"4","key":"pone.0300594.ref022","doi-asserted-by":"crossref","first-page":"329e34","DOI":"10.1002\/jso.23232","article-title":"Aggressive locoregional management of recurrent peritoneal sarcomatosis.","volume":"107","author":"JM Baumgartner","year":"2013","journal-title":"J Surg Oncol"},{"key":"pone.0300594.ref023","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.ejso.2021.10.013","article-title":"Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal sarcomatosis-A systematic review and meta-analysis.","volume":"48","author":"LCK Wong","year":"2022","journal-title":"Eur J Surg Oncol."},{"key":"pone.0300594.ref024","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"WJ Van Driel","year":"2018","journal-title":"N Engl J Med"},{"key":"pone.0300594.ref025","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1200\/JCO.2008.17.8871","article-title":"Aggressive Surgical Policies in a Retrospectively Reviewed Single-Institution Case Series of Retroperitoneal Soft Tissue Sarcoma Patients.","volume":"27","author":"A Gronchi","year":"2009","journal-title":"JCO"},{"key":"pone.0300594.ref026","doi-asserted-by":"crossref","first-page":"e0272044","DOI":"10.1371\/journal.pone.0272044","article-title":"Survival outcomes of surgery for retroperitoneal sarcomas: A systematic review and meta-analysis","volume":"17","author":"Q Guo","year":"2022","journal-title":"PLoS One"},{"key":"pone.0300594.ref027","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1002\/cncr.30572","article-title":"Post-relapse outcomes after primary extended resection of retroperitoneal sarcoma: A report from the Trans-Atlantic RPS Working Group","volume":"123","author":"AJ MacNeill","year":"2017","journal-title":"Cancer"},{"key":"pone.0300594.ref028","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/jso.24256","article-title":"Long-term outcomes in treatment of retroperitoneal sarcomas: A 15 year single-institution evaluation of prognostic features: Retroperitoneal Sarcomas.","volume":"114","author":"E Abdelfatah","year":"2016","journal-title":"J Surg Oncol"},{"key":"pone.0300594.ref029","doi-asserted-by":"crossref","first-page":"96","DOI":"10.14216\/kjco.20015","article-title":"Retroperitoneal sarcomas: Outcomes of repeated resections.","volume":"16","author":"H Hwang","year":"2020","journal-title":"Korean J Clin Oncol"},{"key":"pone.0300594.ref030","doi-asserted-by":"crossref","first-page":"100526","DOI":"10.1016\/j.xcrm.2022.100526","article-title":"Ligand-mediated PAI-1 inhibition in a mouse model of peritoneal carcinomatosis","volume":"3","author":"J Hendrikson","year":"2022","journal-title":"Cell Reports Medicine"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0300594","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T17:50:05Z","timestamp":1712253005000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0300594"}},"subtitle":[],"editor":[{"given":"Murat","family":"Akand","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,4,4]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0300594","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,4]]}}}